Get 250+ investors tailored to your startup

Invest in your industry and stage
Emails & contact info included
Excel and CSV export
Automatically

Trusted by 3,000+ startups

Top 50 Health Care VC Funds in Switzerland

Last updated: Apr 2024 A list of 50 VC funds that invest in Health care startups based in Switzerland. We rank investors based on the number of investments they made in Health care companies from Switzerland. We update this investor list every month.

Top 50 Health Care VC Funds in Switzerland

Investor	Health Care Switzerland investments
Zürcher Kantonal Bank	47
Verve Ventures	36
Foundation for Technological Innovation (FIT)	28
BioMedPartners	17
VI Partners	15
Redalpine	13
Eclosion SA	12
Schroder Adveq	9
SICTIC	9
M Ventures	9
HTGF \| High-Tech Gruenderfonds	9
Kinled Holding	8
3wVentures	8
Bernina BioInvest	8
StartAngels Network	8
GoBeyond	8
Polytech Ventures	8
4FO Ventures	7
Fongit Seed Invest	7
Alpana Ventures	7
Zühlke Ventures AG	6
EQT Life Sciences	6
Sofinnova Partners	6
BlueOcean Ventures	6
Founderful	6
b2venture (formerly btov Partners)	6
OCCIDENT	6
Novartis Venture Fund	6
Swisscom Ventures	6
Versant Ventures	6
Novo Holdings	6
Pureos Bioventures	5
Joyance Partners	5
Endeavour Vision	4
Innosuisse	4
Good Seed Ventures	4
Sunstone Life Science Ventures	4
Nina Capital	4
Lichtsteiner Foundation	4
Privilege Ventures	4
Index Ventures	4
Translink Capital	4
Neomed Management	4
Startfeld	4
New Enterprise Associates	4
Aravis Ventures	4
ETH Zurich Foundation	4
EIT Health	4
Aargauische Kantonalbank	3
Aglaia BioMedical Ventures	3

Find investors that fund startups like yours. Automatically.

Our algorithm will find investors that invest in your industry, stage, and geography.

Investor list

Zürcher Kantonalbank - as an independent, incorporated public-law institution - is wholly owned by the canton of Zurich.

Investment focus

Health Care, Medical Device, Biotechnology
Seed, Series A, Funding Round
Switzerland, Japan, Spain

Portfolio highlights

Odne — Curing with light
ARTIRIA Medical — Artiria Medical empowers catheters and guidewires. We develop cutting edge technologies to revolutionize the limits of neurointerventional procedures, enabling a seamless navigation and stroke treatment.
Cultivated Biosciences — Cultivated - Creamy, dairy-free indulgence

Verve Ventures has invested in more than 140 science and technology startups. We support visionary and resilient entrepreneurs from day one and are a reliable partner for the entire journey. We typically invest EUR 1-3m in early as well as later stage rounds of European high tech startups.

Investment focus

Health Care, Software, Biotechnology
Series A, Seed, Series B
Switzerland, Germany, France

Portfolio highlights

Aktiia — Founded in Switzerland in May 2018 out of a passion to turn insights into action in the fight against hypertension, Aktiia’s groundbreaking medical technology provides people and their physicians comprehensive insights into blood pressure patterns that will inform the diagnosis and management of hypertension. Now available in the United Kingdom,Aktiia has received its CE Mark as a Class IIa medical device - signifying that the device has been assessed to meet high safety, health and environmental protection requirements in Europe. To learn more, visit Aktiia.com.
Groover — Groover is the best way to promote your music to blogs, radios, record labels, & Spotify playlisters. Get listened to, receive coverage & guaranteed feedback!
ARTIRIA Medical — Artiria Medical empowers catheters and guidewires. We develop cutting edge technologies to revolutionize the limits of neurointerventional procedures, enabling a seamless navigation and stroke treatment.

The Foundation for Technological Innovation (FIT) has been helping startups since 1994, encourages entrepreneurship & supports innovation.

Investment focus

Health Care, Biotechnology, Information Technology
Debt Financing, Grant, Seed
Switzerland, France

Portfolio highlights

Voltiris — Voltiris filters natural sunlight to transmit it to plants and recycle the "wasted" sunlight into green electricity.
PeriVision — At Perivision, we combine artificial intelligence (AI), virtual reality (VR) and the cloud to build the next generation systems to understand visual function. Our systems improve workflow efficiency in practices and hospitals and provide deeper clinical insight into eye diseases.
SwissInspect — SwissInspect is a platform for traceable structural digital twins of infrastructure. Detect and quantify damage using state of the art ai models.

BioMedPartners is one of the leading European venture capital firms providing private equity and mezzanine financing to early- and mid-stage healthcare and human life science companies. They target the entire industry with special focus on pharmaceuticals, biotechnology, diagnostics and medical technology.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
Switzerland, Germany, France

Portfolio highlights

Tricares — TRiCares is a medical device company, devoted to developing a catheter-based valve replacement system for minimal invasive treatment of tricuspid valve regurgitation.
ImmunOs Therapeutics — ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease.
Tubulis — Reimagining Antibody Drug Conjugates Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its pipeline and

VI Partners are Venture Capitalists successfully financing outstanding teams and innovations in the Healthcare and Technology space since 20 years.

Investment focus

Health Care, Biotechnology, Medical Device
Series A, Series B, Series C
Switzerland, Germany, United States

Portfolio highlights

Xeltis — Xeltis is pioneering a restorative approach in cardiovascular therapy.
LeaseTeq — LeaseTeq bietet Privat- sowie Unternehmenskunden das erste komplett digitale Leasingangebot.
Unique — Try Unique Finance GPT to increase productivity by automating manual workload through AI and ChatGPT solutions.

redalpine is a thesis-driven vc with deep expertise in software and science. since 2006. we believe in the power of big ideas and in empowering game changers. we don't just invest, we co-create a better tomorrow. together with you.

Investment focus

Software, Biotechnology, Health Care
Series A, Seed, Series B
Germany, Switzerland, United Kingdom

Portfolio highlights

Aktiia — Founded in Switzerland in May 2018 out of a passion to turn insights into action in the fight against hypertension, Aktiia’s groundbreaking medical technology provides people and their physicians comprehensive insights into blood pressure patterns that will inform the diagnosis and management of hypertension. Now available in the United Kingdom,Aktiia has received its CE Mark as a Class IIa medical device - signifying that the device has been assessed to meet high safety, health and environmental protection requirements in Europe. To learn more, visit Aktiia.com.
Infinite Roots — Mushlabs is a biotech company using fermentation to create the next generation of sustainable foods from the roots of mushrooms.
Morressier — A platform geared towards the scientific community. From managing abstracts to presenting research content in a virtual conference or in-person meeting.

Eclosion assists entrepreneurs with the necessary resources to bridge the gap between their laboratories and the stage where the start-up

Investment focus

Biotechnology, Pharmaceutical, Health Care
Seed, Series C, Funding Round
Switzerland

Portfolio highlights

KYLYS — KYLYS is an innovative Swiss company based in Geneva founded in March 2017. KYLYS provides people and patients with highly effective and safe products based on biomolecules.
Genkyotex — Genkyotex is dedicated to the development of innovative drugs which block enzymes that produce oxygen radicals. Such novel drugs will allow the treatment of oxygen-radical mediated acute and chronic diseases, with improved specificity, safety, and efficacy over existing antioxidants therapy, giving them a significant competitive advantage.Genkyotex targets its technology initially to the therapeutic areas of cardiovascular, metabolic and neurodegenerative diseases.
MPC Therapeutics — MPC Therapeutics develops a novel class of compounds with application in Immunotherapy and Metabolic diseases

Schroders Capital provides investors with access to a broad range of private asset investment opportunities, portfolio building blocks and customised private asset strategies. With over $65 billion assets under management, we offer a diversified range of investment strategies, including real estate, private equity, secondaries, venture capital, infrastructure, securitised products and asset-based finance, insurance-linked securities and impact investing.

Investment focus

Biotechnology, Health Care, Therapeutics
Series B, Series C, Series A
Switzerland, United States, India

Portfolio highlights

Lenskart — Lenskart, the first of its kind online optical store in India, has made it possible to acquire a good quality pair of specs with prescription lenses for just Rs. 399, all this while you sit in the comfort of your home. With a 48-hour free home delivery guarantee and 365 days return policy, Lenskart.com is doing what e-commerce hasn’t been able todo in India yet.The website has over 500 designs of eye frames, in multiple colors, for all age groups, from Rs. 399 all the way to Rs. 4,000 for a pair. All one needs to do is select a frame, fill in their power, and place an order. You can pay online or at the time of delivery.Lenskart.com has the biggest collection of discounted contact lenses consisting of all top-notch brands (viz. Johnson & Johnson, Bausch & Lomb, Ciba Vision are to name a few) and be it disposable, toric, colored or bifocal contact lenses, you can find all possible types here. Lenskart is dedicated to providing its customers with a simple, hassle-free way to replace their contact lenses. One can receive the exact same contact lens, their doctor prescribed, delivered to their door, at a great price.
HAYA Therapeutics — Pioneering next-generation therapies for fibrotic diseases. Learn more about our approach here.
ImmunOs Therapeutics — ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease.

How to Invest in Swiss Startups That Last The SICTIC Investor community helped to fund to more than 254 Swiss tech startups to date. While doing so, they learned a lot about what to watch out for and how to foster success. Read more Get your FREE angel handbook Services For Startups We invite all

Investment focus

Software, Artificial Intelligence, Information Technology
Seed, Pre-Seed, Funding Round
Switzerland, Germany, United Kingdom

Portfolio highlights

Gaia Tech — Gaia Technologies turns agricultural sidestreams into high-value ingredients for cosmetics, food, and feed manufacturers.
PeriVision — At Perivision, we combine artificial intelligence (AI), virtual reality (VR) and the cloud to build the next generation systems to understand visual function. Our systems improve workflow efficiency in practices and hospitals and provide deeper clinical insight into eye diseases.
Health Yourself — Health Yourself is making routine healthcare services available digitally and from home. So far, we are offering lab tests from home, medication subscriptions and personalised supplements for health concerns ranging from sexual health to prevention.

Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Seed
United States, Switzerland, United Kingdom

Portfolio highlights

Nouscom — Nouscom is a next-generation immunotherapy company developing genetic cancer vaccines and oncolytic viruses..
DISCO Pharmaceuticals — DISCO Pharmaceuticals is a firm that specializes in large-scale surfaceome unlocking of cancer cells.
Polaris Electro-Optics — Polaris Electro-Optics empowers integrated photonics for communications and computation.

The seed investor High-Tech Gründerfonds (HTGF) finances tech start-ups with growth potential and has supported more than 700 start-ups since 2005. With the launch of its fourth fund, HTGF now has about 1.4 billion euros under management. Its team of experienced investment managers and start-up experts support young companies with expertise,entrepreneurial spirit and passion. HTGF’s focus is on high-tech start-ups in the fields of digital tech, industrial tech, life sciences, chemistry and related business areas. To date, external investors have injected about 5 billion euros of capital into the HTGF portfolio via more than 2,000 follow-on financing rounds. In addition, HTGF has already successfully sold shares in more than 170 companies. Fund investors in this public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital and 45 companies from a wide range of industries. Fund investors in this public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital and 45 companies from a wide range of industries.

Investment focus

Software, Information Technology, Biotechnology
Seed, Series A, Funding Round
Germany, Switzerland, United States

Portfolio highlights

Graswald — Graswald engages in the creation of natural and digital 3D worlds for the entertainment industry.
CustomSurg — RETHINKING TRAUMA SURGERY At CustomSurg we are changing the treatment of complex bone fractures from a subjective to an objective approach, through personalized solutions.
Tubulis — Reimagining Antibody Drug Conjugates Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its pipeline and

Kinled was founded in 1980 to retain the investment assets of the Aisher family.In 1990, the investment focus shifted to a portfolio of early stage investments applying Kinled’s company development experience alongside the endurance and passion of family owned investments together with the strategic focus of venture capitalists.Since then,Kinled has taken 8 companies to public markets and many more to successful trade sales at significant multiples.

Investment focus

Biotechnology, Health Care, Financial Services
Seed, Funding Round, Series A
United Kingdom, United States, Switzerland

Portfolio highlights

Xapien — Xapien delivers automated insight reports on companies and individuals in minutes, so you can make informed business decisions quickly and with confidence.
OneTrust — OneTrust is a provider of privacy management and marketing compliance technology that helps organizations comply with global regulations. It automates privacy impact assessments and data inventory mapping, enforces risk remediation actions, and triggers recurring audits for continuous compliance monitoring across customer, employee, and vendor datatransfers. Its web-based software can be accessed on any device and provides a single place for a private office to collaborate with business groups, vendors, and trusted advisors managing privacy risks. The result is the ability to demonstrate privacy by design and ongoing compliance with policies, data privacy laws (GDPR, BCR, Privacy Shield), and other privacy frameworks (HITECH, ISO, GAPP, APEC).The company was founded in 2016 and is headquartered in Atlanta, Georgia.
Connect Earth — Connect Earth is an environmental data company that builds the infrastructure for climate-conscious products by aggregating and standardising environmental data and making it available through developer-first toolkits. The core product is an API solution that calculates the carbon impact of spend-based financial transactions of consumers and companies.

3wVentures provides seed money and venture capital to international internet startups. As they focus on early stage projects and prototypes, our investments and co-investments target a volume of up to USD 250,000.

Investment focus

Software, Health Care, Information Technology
Seed, Angel, Series A
Switzerland, Spain, Austria

Portfolio highlights

Abionic — Abionic SA is ideally positioned at the boundaries of medical technology, biotechnology and nanotechnology. As a spin-off from EPFL (Swiss Federal Institute of Technology Lausanne, Switzerland), Abionic uses these highly advanced technologies to provide the medical profession with a novel diagnostic tool designed to give patients personal allergyprofiles. Abionic aims to become an important international player in the field of personalized medicine, in particular in allergy detection.Abionic SA is a certified ISO 9001/13485 company, including research, development and commercialization of in vitro diagnostic devices for allergies detection. The standard ISO 13485 specifies requirements for a quality management system where an organization has to demonstrate its ability to provide medical devices and related services that consistently meet customer and regulatory requirements.Abionic SA is a privately owned high-tech company and is strongly supported by the Swiss Federal Institute of Technology of Lausanne (EPFL), The Canton of Vaud and Venturelab.Abionic was founded by former scientists from the biomedical optics laboratory (LOB) at EPFL. Its headquarters are located in Lausanne, Switzerland.Abionic appreciates the support it has received from:
GUURU — Connect your customer community with your online shoppers to enable relevant, real-time advice from the people who love and use your products.
Pregnolia — Pregnolia ensures that every woman can have a happy, healthy and informed pregnancy until term. Their team knows that the existing research about preterm birth assessment is very promising, but this alone does not guarantee success. Sabrina, Francisco and Annette are highly committed to develop the commercial version of the device, complete theclinical trial, follow the regulatory roadmap and execute on their business vision to successfully support gynaecologists in improving the preterm birth risk assessment and birth management.

Bernina BioInvest is an investment Firm.

Investment focus

Biotechnology, Health Care, Biopharma
Seed, Series A, Series B
Switzerland

Portfolio highlights

HAYA Therapeutics — Pioneering next-generation therapies for fibrotic diseases. Learn more about our approach here.
Memo Therapeutics — Memo Therapeutics AG (MEMO) is an innovator in the field of antibody discovery and immune repertoire analysis.Its MemoMAB™ platform creates a recombinant in vitro copy of an individual’s B cell / antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’simmune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. This leads to entirely new possibilities in immune repertoire analysis and antibody discovery.MemoMAB™ is deployed in proprietary antibody lead discovery programs and is made available in collaborations.
Synendos Therapeutics — Synendos Therapeutics is a biopharmaceutical company that aims to develop breakthrough safe and effective therapies for unmet needs in neuropsychiatric disorders through modulation of a new drug target in the endocannabinoid system that enables restoration of natural functioning of the brain.

StartAngels Network is a Zurich-based angel investment firm that provides investment consulting services.

Investment focus

Medical Device, Health Care, Medical
Seed, Series A, Series B
Switzerland, Brazil

Portfolio highlights

Medyria — Medyria is a Swiss medtech startup that engineers technologies for cardiovascular catheter navigation and sensing. They develop a unique guiding and sensing medical device based on proprietary Blood Flow Velocity Sensor technology. The TrackCath System is designed to be cost-effective and safe during EVAR procedures.Medyria's goal is todevelop devices that enable safer and more effective endovascular procedures. It was founded in 2014 and is based in Winterthur, Zurich, Switzerland.
Pipra — PIPRA AG (Pre-Interventional Preventive Risk assessment) is developing a cutting-edge AI-based pre-operative test to assess a patient's risk of suffering from cognitive disorders after surgery.
Hylomorph — Hylomorph is a clinical-stage medical device company developing innovative materials designed to transform the biocompatibility of implantable medical devices.

GoBeyond is a FinTech company transforming angel investing into a new scalable asset class for small and large, novice to experienced investors. It offers a unique deal platform, portfolio tools, syndication/pooling, due diligence, investment monitoring services, training and certified deal leaders.Its clients are individuals, familyoffices, professional groups and corporations. It is active in the EU, Switzerland and the US. GoBeyond also offers educational training modules for angel investors in 11 categories.

Investment focus

Information Technology, Medical, Software
Funding Round, Seed, Series A
Switzerland, Germany, United Kingdom

Portfolio highlights

LEND — LEND provides peer to peer lending in Switzerland. It connects investors with borrowers. Moreover, investors earn substantial returns and borrowers benefit from low interest rates. The company is based in Switzerland and it was founded in 2015.
AVAtronics — AVA Active Noise Cancellation (ANC) Solution is a breakthrough in Audio Industry. AVA is the first and only TRUE WIDE-BAND ANC in the market capable of selectively cancelling all annoying noises we want to get rid of without compromising the quality of Music or speech.
Blumer — Blumer is a social networking platform that provides social networks that can monetize time by consuming advertisements, selling nfts, and making crypto transactions. It offers social networks, crypto, digital marketing, and blockchain.

Polytech Ventures are an early stage VC firm based in Switzerland with a strong international focus. Their strategic location at EPFL in Lausanne grants us access to one of the most dynamic and recognized innovation centers in the world

Investment focus

Financial Services, FinTech, Software
Seed, Series A, Funding Round
Switzerland, United States, Spain

Portfolio highlights

yamo — Frische Bio-Kindernahrung von yamo, so lecker wie selbstgemacht und kostenlos direkt zu dir nach Hause geliefert. Jetzt probieren und profitieren.
Relai — Relai is a Bitcoin investment app that allows anyone to buy bitcoin within one minutes or set up an automated savings plan.
Earny — Payroll management built for Startups & SMEs. Swiss payroll service with no hidden fees & no hassle

4FO Ventures

Investment focus

Artificial Intelligence, Health Care, Medical
Series A, Seed, Series B
Switzerland

Portfolio highlights

Positrigo — NeuroLF is an ultra-compact brain Positron Emission Tomography system. Our technology makes functional imaging accessible for people worldwide.
Ecorobotix — ecoRobotix contributes to an agriculture that respects the environment, focusing on soil and hydrological resources conservation and using a minimum amount of energy. ecoRobotix aims to offer precise, safe, reliable and affordable robotic solutions that simplify farmers’ life to produce healthy food. In particular, its revolutionary solar-poweredweeding robot offers a more sustainable use of herbicides while reducing farmers costs.
ARTIRIA Medical — Artiria Medical empowers catheters and guidewires. We develop cutting edge technologies to revolutionize the limits of neurointerventional procedures, enabling a seamless navigation and stroke treatment.

Fongit Seed Invest (FSI) is the leading Seed Money Fund of Switzerland for young technology companies. It provides smart seed capital.

Investment focus

Health Care, Medical, Biotechnology
Seed, Series A, Series B
Switzerland

Portfolio highlights

EBAMed — EBAMed SA is a Swiss startup based in Geneva whose mission is to enable safe and effective non-invasive treatments of heart arrhythmias with protontherapy. The company is currently developing a medical device to enable non-invasive heart motion imaging and real-time synchronization of the therapeutic beam. This device consists in both hardware andsoftware components and expands treatment possibilities for existing protontherapy centres, enabling them for the first time to treat heart patients.
Gmelius — Gmelius is the world's first 360 email collaboration platform designed for Gmail and your company's daily apps. Join the async movement!
Annaida Technologies — Annaida Technologies has developed a groundbreaking device, EmbryoSpin, that performs microscopic Nuclear Magnetic Resonance (“µNMR”) at a scale 10-fold better than existing technologies.

Alpana Ventures is a Swiss VC focusing on digital transformation.Since 2016 we backed 45 founder teams with 3 Funds, supporting them in their journey towards a positive impact.Committed to value creation, we discover deep tech solutions in Switzerland, Europe and the US.We invest to embed them into innovative business models and back them tobecome global market leaders.Applying ESG criteria, our portfolio companies help create a more sustainable future.

Investment focus

Software, FinTech, Information Technology
Seed, Series A, Funding Round
United States, Switzerland, Germany

Portfolio highlights

Sinay — Use the full potential of your data with intelligent solutions. Become more efficient on a daily basis and reduce your environmental impact.
Nezasa — Nezasa’s travel booking solution empowers travel brands globally to combine all planning and booking related actions into one seamless end-to-end experience.Our tools, enable to plan and book any type of multi-product or multi-stop itinerary.TripBuilder Hyper-personalised packaging Real-time planning and booking of personalised itinerariesPowerful, easy to use and very interactive Deep integration possibilities into existing fulfilment landscapes Enterprise-grade, proven with large TO customersTripBooster Hyper-personalised In-Destination Upselling The extension of TripBuilder’s power throughout the entire travel lifecycle The perfect travel companion Seamless purchasing of perfectly fitting additional products Smart upselling recommendation, available in both a push and pull mode
Tinamu — Tinamu Labs has developed a technology that converts commercially available drones into camera equipment reaching professional standards.

Zühlke Ventures AG is a venture capital arm of Zühlke Technology Group AG specializing in financing of start-ups at an early stage and providing growth capital. It seeks to invest in the technology and medical devices companies. It typically invests in German-speaking Europe and Great Britain.

Investment focus

Health Care, Medical Device, Biotechnology
Series A, Seed, Series B
Switzerland, Sweden, United States

Portfolio highlights

Evismo — Evismo provides diagnostics services in Switzerland
Healios AG — Healios CTMS provides the Digital Biomarker based technology and digital validation scales to improve and streamline research and clinical practice.
Flow Neuroscience — Flow Neuroscience is a healthcare company that develops depression treatment devices that combines an easy-to-use brain stimulation headset with a personalized mobile app to target both the physical and behavioral elements of Major Depressive Disorder (MDD). The company's wearable stimulates a patient's left frontal lobe, the area of thebrain that has often lowered activity in people suffering from depression.Flow Neuroscience combines their wearable with a mobile app that nudges users to behaviors that will help lessen the effects of their depression, including exercise and regular sleeping patterns.The company's hope is to make available for the public a treatment that's currently only used in clinics specialized in brain stimulation. It also wants to make the treatment affordable enough to seriously challenge a dominant pharmaceuticals industry.

EQT life science develops innovative medicines, devices, and tools to address the single important thing that matters to the preservation of health. The organization believes that such opportunities add value to all stakeholders.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, The Netherlands, Switzerland

Portfolio highlights

Onera Health — Introduction to Onera sleep diagnostics and monitoring solutions
Vico Therapeutics — Vico Therapeutics is a developer of ribonucleic acid (RNA) modulating therapies for rare neurological disorders. The company discovers, develops, and delivers therapies for CNS disorders. Its initial focus is on SCA which is a subgroup of hereditary ataxia, HD which is a neurodegenerative disorder, and RTT-a neurodevelopmental disorder primarilyaffecting girls that enable clients with providing therapy for it.Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Judith van Deutekom, and Gail Mandel and it is headquartered in Leiden, The Netherlands.
Tubulis — Reimagining Antibody Drug Conjugates Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its pipeline and

Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
France, United States, United Kingdom

Portfolio highlights

Cure51 — Cure51 mission is to create a database of cancer survivors to leverage their exceptional biological features and find new drugs to cure Cancer.
Bioptimus — Our mission is to build the first universal AI foundation model for biology to fuel breakthrough discoveries and accelerate innovations in biomedicine and beyond.
MISSION Therapeutics — Deubiquitylating enzymes: multiple drug opportunities across therapeutic areas

BlueOcean Ventures SA provides capital, operational and company development advisory support (mentoring, company management, divestment experience, network, negotiation support) to entrepreneurs in Switzerland. BlueOcean Ventures is based in Geneva, Switzerland.

Investment focus

Health Care, Medical, Personal Health
Series A, Seed, Series B
Switzerland, India, France

Portfolio highlights

nPloy — Simply set your filters and get matched with your dream job! Let top employers apply for you & connect with them via chat or a video call.
CyanoGuard AG — Our award-winning cyanide testing and optimizing solution is ideal for the mining, food, and medical field. It's easy to use, digital and offers real-time data.
99RetailStreet — 99RetailStreet is an eCommerce Cloudplatform for the unorganized Retail business in the developing countries. Our ecosystem targets Retailers, Distributors, and Manufacturers. 99RetailStreet provides POS solutions to Retailers, Real-Time Analytics to Manufacturers and Distributors

Wingman Ventures is Switzerland’s leading pre-seed fund backing founder teams building tech companies with the potential to become global market leaders. We have a track-record of supporting exceptional founders in creating breakthrough companies and it is our passionate conviction that the Swiss startup ecosystem is just starting to write its bestsuccess stories.As founders, we always valued feedback from experienced entrepreneurs. In fact, it was critical to our success.Wanting to dedicate our know-how, experience and energy to the new generation of startup founders, we founded Wingman Ventures. As wingmen and wingmates we fly on the wings of ambitious founder teams and help them navigate around storms and avoid severe turbulences on their way to building successful companies.

Investment focus

Software, Artificial Intelligence, SaaS
Seed, Pre-Seed, Series A
Switzerland, United Kingdom, Canada

Portfolio highlights

Nala Earth — Nala empowers companies to measure, manage and report their impact and dependency on nature - compliant with regulation.
Chiral — Next-generation electronics with nanomaterials
Cultivated Biosciences — Cultivated - Creamy, dairy-free indulgence

B2venture is a venture capital firm focused on early-stage investments in digital and industrial technology companies. B2venture invests EUR 100m+ per year in high-growth companies with ticket sizes from EUR 0.25m to 3.5m.

Investment focus

Software, Health Care, Information Technology
Series A, Seed, Series B
Germany, Switzerland, United Kingdom

Portfolio highlights

Yendou — We make it unbelievably easy, for clinical operations teams, to manage site selection activities for oncology clinical trials.
DUDE CHEM — DUDE CHEM is a leading company in green chemical manufacturing based in Berlin.
Aeovian Pharmaceuticals — Aeovian is a San Francisco based biopharmaceutical company developing novel and highly selective therapeutics modulating mTORC1 pathway.

Occident is an international, privately held investment company based in Zug and Munich. Our goal is to manage our own wealth in a sustainable, meaningful manner seeking to make a positive contribution to society through our investments. Venture Capital is the focus of our investment activities. We see ourselves as a long-term oriented enabler forinnovative start-ups and visionary founders. As a complementary team of experts, we are fascinated by technologically sound topics (deep tech) from the life sciences, digital and high-tech sectors with the potential to decisively improve people's lives.

Investment focus

Health Care, Medical Device, Biotechnology
Series A, Series C, Funding Round
Germany, Switzerland, Slovenia

Portfolio highlights

ReCatalyst — REvolutionizing the way we make fuel cell CATALYSTs
Tubulis — Reimagining Antibody Drug Conjugates Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its pipeline and
Lunaphore — Lunaphore Technologies is a spatial biology company, building multiplex immunofluorescence & IHC solutions for discovery and immuno-oncology research

Learn about the approach the Novartis Venture Fund takes to investing in innovative life science companies developing biotechnology and biopharmaceutical therapeutics that address unmet patient needs.

Investment focus

Biotechnology, Health Care, Therapeutics
Series B, Series A, Series C
United States, Switzerland, United Kingdom

Portfolio highlights

Hyku — Hyku Biosciences is developing the next generation of covalent medicines by targeting histidine, tyrosine and lysine binding pockets in disease-causing proteins.
Fore Biotherapeutics — We are a precision oncology company pioneering the development of cancer therapies guided by our proprietary functional genomics.
Hepalink — Hepalink is a manufactures ultra-pure pipeline control systems based on semiconductors and pan-semiconductor liquid circuits.

Swisscom Ventures is an venture capital arm of Swisscom AG, that specializes in early stage tech investments founded in 2007.Swisscom Ventures invests in growth companies with emerging business models and technologies of strategic relevance to Swisscom's core business. As a value-add investor, Swisscom brings its investees the technicalexpertise and strategic insights of an incumbent telecom operator. We act as a bridge to Swisscom's operational business units, which portfolio companies can also leverage as a test environment for their products and services.Swisscom Ventures seeks minority stakes in companies related to the information/communications/entertainment space.

Investment focus

Software, SaaS, Information Technology
Funding Round, Series B, Series A
Switzerland, United States, United Kingdom

Portfolio highlights

rready — Boost internal innovation and engage employees with ready-to-use programs, accompanied by experts in intrapreneurship.
Pexapark — We make PPAs for renewables simple. Master your wind and solar power purchase agreements and get the tools to manage merchant risk.
Spacetek Technology AG — Our process control instruments measure gases in real time, delivering a full quantitative chemical analysis up to ten times per second.

Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
United States, Switzerland, Canada

Portfolio highlights

Nouscom — Nouscom is a next-generation immunotherapy company developing genetic cancer vaccines and oncolytic viruses..
Firefly Bio — Firefly specializes in Degrader Antibody Conjugates (DACs) which combine the unique strengths of ADCs with selective protein degraders.
Tentarix Biotherapeutics — Enabling intelligent therapies with multifunctional biologics.

Novo Holdings is a world-leading life science investor with a focus on creating long-term value.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
United States, Denmark, United Kingdom

Portfolio highlights

Revagenix — Game-changing approach to anti-infectives
Orbis Medicines — Orbis Medicines is a novel macrocyclic chemistry and computational platform for high-throughput drug discovery.
Claris Biotherapeutics — Claris Biotherapeutics develops a topical formulation intended to cure corneal wounds, ulcers, and scars. The formulation creates a recombinant hepatocyte growth factor which accelerates the healing process, providing healthcare providers noninvasive therapeutic treatment.

Venture capital for companies developing innovative therapeutics.

Investment focus

Biotechnology, Therapeutics, Health Care
Series A, Series B, Series C
Switzerland, France, The Netherlands

Portfolio highlights

Minervax — MinervaX is pursuing the development of a vaccine against Group B streptococcus (GBS) infections by utilizing a particular fusion protein : click to read more
Memo Therapeutics — Memo Therapeutics AG (MEMO) is an innovator in the field of antibody discovery and immune repertoire analysis.Its MemoMAB™ platform creates a recombinant in vitro copy of an individual’s B cell / antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’simmune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. This leads to entirely new possibilities in immune repertoire analysis and antibody discovery.MemoMAB™ is deployed in proprietary antibody lead discovery programs and is made available in collaborations.
PulseSight Therapeutics — PulseSight is an ophthalmology drug development company creating novel, non-viral gene therapies with minimally invasive delivery technology to address the unmet need for treatments against severe retinal diseases leading to blindness.

Joyance Partners is the first venture fund supporting companies that deliver Delightful Moments derived from science - a new, transformative cycle of human experience that we see as one of the greatest investment opportunities in decades.

Investment focus

Health Care, Biotechnology, Wellness
Seed, Series A, Pre-Seed
United States, Germany, Switzerland

Portfolio highlights

mybacs — mybacs is a DTC, research-driven, Biotechnology company specialized in the human microbiome. Our goal is to revolutionize the market around intestinal healthcare and thus make a decisive contribution to the daily well-being of our customers. Our team of pharmaceutical scientists and physicians is focused on the development of innovative andhighly-dosed synbiotic supplements. These are aligned by our singular formulations from specifically selected probiotic cultures, prebiotics as well as minerals and vitamins tailored to the individual needs of our customers.
Amatera — Amatera is a biotechnology research company that leverages the latest techniques in biotechnology, to create coffee varieties. Amatera urges to make coffee varieties more sustainable and climate resistant to fill that massive demand. Founded by Omar Dekkiche and Lucie Kriegshauser in 2022 and is located in Paris, France.
Sunnyside — Cutback Coach is a developer of an alcohol tracking app to help people build healthier habits around their drinking. It offers a custom plan based on current drinking habits and goals, then set a daily reminder via text message that help users set the limit of their drinking habit.

Endeavour Vision is an investment advisory firm focused on transformative healthcare technologies.

Investment focus

Health Care, Medical, Biotechnology
Series C, Series B, Series A
United States, Switzerland, France

Portfolio highlights

Venture Med Group — VentureMed Group (VMG) designs, develops and markets innovative medical devices which enable interventionalists to cost effectively treat peripheral artery diseases and improve the lives of their patients.Founded by physicians who understand the clinical, medical and financial demands in today’s healthcare environment, VMG creates truly costeffective solutions. Their flagship product, the FLEX Scoring Catheter enables providers to reduce expensive inventory costs while offering the interventionalist more treatment options from a single device.
Relievant Medsystems — Relievant's mission is to provide patients with low risk therapy that can alleviate their back pain.
Virtual Incision — Virtual Incision is reimagining robotic support for minimally invasive (MIS) procedures with simple innovations offering mobility, flexibility, and accessibility to provide MIS options to more patients. It has develops the MIRA® (Miniaturized In vivo Robotic Assistant) Platform, a first-of-its-kind miniaturized surgical robotic support device,focusing first on colon resection, with follow-on specialty robots for additional potential applications.

Innosuisse’s role is to promote science-based innovation in the interests of industry and society in Switzerland.

Investment focus

Health Care, Biotechnology, Medical Device
Grant, Pre-Seed, Seed
Switzerland, United States, Taiwan

Portfolio highlights

Pelt8 — Pelt8 enables climate action through the platform with scalable processes and controls to collect sustainability-related data in an easy and traceable way.
Atinary — Atinary is an end-to-end AI, machine learning, robotics, and cloud computing technology platform for digitizing R&D operations.
Ascento — Secure, maintain, and inspect outdoor assets by reducing the intervention times and augmenting data capturing capability.

Good Seed Ventures is a Venture Capital firm that exclusively invests in sustainable food tech.

Investment focus

Food and Beverage, Food Processing, Biotechnology
Seed, Series A, Pre-Seed
Germany, Israel, United States

Portfolio highlights

Lovely Day Foods — We harness the power of plants and cutting-edge technology to crack the egg.
Libre Foods — Libre Foods is a biotech startup on a mission to liberate the food system and create a more free future for people, the planet, and animals. The company was founded in 2020 and is based in Barcelona, Catalonia, Spain.
Nosh Biofoods — We create nutritional and highly functional proteins from non-GMO fungi. Our proprietary ferementation process is minimal, scalable, and sustainable.

Sunstone Life Science Ventures is an independent European venture capital investment firm. We enable and empower life science therapeutics innovations.

Investment focus

Biotechnology, Health Care, Medical
Funding Round, Series B, Series A
Denmark, Sweden, Switzerland

Portfolio highlights

Kynexis — Kynexis is leading the way in precision medicine, focusing on the treatment of cognitive impairment associated with schizophrenia (CIAS). Explore our innovative approach and our dedication to improving the lives of millions globally.
Teitur Trophics — Teitur Trophics is a biotech company developing circular peptides for neurodegenerative diseases. The company was founded in 2020 and is headquartered in Aarhus, Denmark.
Rewind Therapeutics — Rewind Therapeutics is a developer of novel therapeutics intended to facilitate the treatment for neurological diseases.The company's first-in-class remyelinating therapeutics block inhibitory signals that prevent the expansion and migration of oligodendrocyte stem cells in order to promote effective remyelination, enabling medicalpractitioners to treat patients suffering from multiple sclerosis and other myelin-related diseases with efficacy.

We deploy early stage capital to fuel the growth of need-driven health technology companies.

Investment focus

Health Care, Artificial Intelligence, Software
Seed, Pre-Seed, Series A
United States, United Kingdom, Austria

Portfolio highlights

Ryver — We provide software to generate synthetic medical images and assess their privacy as well as quality
CryoCloud — CryoCloud Accelerate your protein structure determination - Bring your cryo-EM data analysis to the next level by using our cloud-based image analysis workflow.
Zetta Genomics — Zetta Genomics unleashes the power of genomic data to improve health outcomes for millions of patients around the world - and realise the potential of

Boosting health pioneers. We invest in early stage start-ups in different sectors: medtech, life science, biotech, mental health, public health, well-being.

Investment focus

Medical, Health Care, Biotechnology
Seed, Series A
Switzerland

Portfolio highlights

Microcaps — Microcaps provides a novel solution to encapsulate ingredients naturally, protect them an enhance them with high-end appearence
Healios AG — Healios CTMS provides the Digital Biomarker based technology and digital validation scales to improve and streamline research and clinical practice.
MUVON Therapeutics — Muvon Therapeutics platform helps women with urinary incontinence and treats diseases based on skeletal muscle degradation, supporting them in their commitment to living a healthy life. The company's mode of contact is by mail, phone, and physical address.

Privilege Ventures is the venture capital arm of Privilège Management and invest in seed and early stage companies. Geographical focus is Switzerland and the rest of Europe. Focus sectors are industrial-tech, med-tech, wearables and in general ICT.

Investment focus

Health Care, Hardware, Software
Seed, Series A, Funding Round
Switzerland, France

Portfolio highlights

Wyth — Wyth makes technologies that help humans create meaningful relationships by bringing emotions, stories and connections beyond the interface.
Smeetz — Smeetz is the future of a unified, data-driven and dynamic pricing-oriented commerce for attractions and cultural venues.
Avelo — Our mission is to save lives by bringing fast and actionable infectious disease diagnosis closer to the patient. Avelo's solution is a breath collection device. It works with existing molecular tests to detect multiple respiratory tract infections causing pneumonia

Index Ventures is an international venture capital firm with dual headquarters in San Francisco and London, investing in technology-enabled companies with a focus on e-commerce, fintech, mobility, gaming, infrastructure/AI, and security.

Investment focus

Software, E-Commerce, Internet
Series A, Series B, Seed
United States, United Kingdom, France

Portfolio highlights

SESO — Seso is a labor solution for agriculture. We provide support with the entire H-2A process, including the H-2A Visa, recruiting farmworkers, H-2A compliance, and digital worker onboarding.
Vizcom — Vizcom is an Ai-powered creative tool designed for design and creative professionals. It offers a transformative approach to concept drawing, enabling users to turn their sketches into impressive realistic renderings quickly and efficiently.
Nourish — Achieve your desired health and wellness through personalized nutrition counseling. Nourish is the easiest way to find a registered dietitian and get it covered by your insurance. Find a dietitian today and start your telehealth appointments.

Translink Capital is a trailblazing Silicon Valley VC with unmatched institutional connections to Asia's economic powerhouses.

Investment focus

Software, Information Technology, Mobile
Series A, Series B, Series C
United States, China, South Korea

Portfolio highlights

Aktiia — Founded in Switzerland in May 2018 out of a passion to turn insights into action in the fight against hypertension, Aktiia’s groundbreaking medical technology provides people and their physicians comprehensive insights into blood pressure patterns that will inform the diagnosis and management of hypertension. Now available in the United Kingdom,Aktiia has received its CE Mark as a Class IIa medical device - signifying that the device has been assessed to meet high safety, health and environmental protection requirements in Europe. To learn more, visit Aktiia.com.
Lionsbot — LionsBot's objective is to empower cleaners with easy-to-use, powerful and smart cleaning robots which help perform and fulfil key cleaning roles - Vacuum, Clean, Scrub, Mop and yes, even Pull.
Plus One Robotics — The fastest and most reliable parcel handing robotics solutions in your warehouse.

NeoMed Management is an international venture capital investment firm, exclusively focused on the healthcare industry. Founded in 1997, NeoMed has established five funds to date.NeoMed invests in emerging companies with outstanding growth prospects. These companies are developing innovative and proprietary medical products that addresssubstantial market opportunities in the pharmaceutical, medical device and diagnostics industries.NeoMed has a multi-stage investment approach and invests at all stages of development from start-up to later stage growth financings. Since inception, NeoMed has successfully invested in more than 30 companies in Europe, including Scandinavia, Switzerland, Germany and the UK, and in North America.From offices in Norway and Switzerland, NeoMed’s experienced investment team works closely with its entrepreneurs and a broader industry network to support the growth of its portfolio companies.NeoMed is currently focusing on NeoMed Innovation IV L.P. and NeoMed Innovation V L.P.

Investment focus

Health Care, Biotechnology, Medical
Series B, Series C, Funding Round
Switzerland, United States, Italy

Portfolio highlights

Sonendo — Sonendo developing innovative technologies to transform dentistry by Saving Teeth Through Sound Science®. The GentleWave® System shows significant improvements in clinical efficacy and practice efficiency when compared to standard root canal treatment.1,2, 3 Sonendo is the parent company of TDO® Software, the developer of the most widely usedendodontic practice management software in the world, designed to simplify practice workflow. TDO software seamlessly integrates practice management, imaging, social media, referral reporting, CBCT imaging, and offers built-in communication with the GentleWave System.
Oxular — Oxular is a clinical-stage retinal therapeutics company that is developing technology to transform the treatment of retinal disease, offering patients life-changing solutions to their unmet needs.
JenaValve Technology — Redefining what it means to treat patients with severe aortic regurgitation.

Startfeld is the innovation and start-up network in the St.GallenBodenseeArea. In every phase of innovation, they support both ambitious entrepreneurs and established SME, who are open to new impulses and development.

Investment focus

Health Care, Wellness, Manufacturing
Seed
Switzerland

Portfolio highlights

Nahtlos — Nahtlos is a developer of a textile ECG carrier without glue intended to provide long-term, continuous monitoring of heart activity. In order to create a modular and highly flexible ECG system, the company's device consists of a ribbon carrier with clip-in electrodes that are based on a patented electrode structure that can be easily adjustedto different body shapes. This allows doctors to increase patient comfort by swapping out the conductive gel used in gel electrodes.
OnlineDoctor — OnlineDoctor is an innovative Swiss-based platform that allows the user to diagnosed any skin problems quickly (within 48h), location-independent and cost-effectively by an independent dermatologist. OnlineDoctor is suitable for the evaluation of all kinds of skin problems such as rash, eczema, birthmark and many more. The company'suncomplicated, high-quality platform provides a service that benefits all parties.
Health Yourself — Health Yourself is making routine healthcare services available digitally and from home. So far, we are offering lab tests from home, medication subscriptions and personalised supplements for health concerns ranging from sexual health to prevention.

Foundational partners to ambitious founders at every stage of company-building.

Investment focus

Software, Health Care, Biotechnology
Series B, Series A, Series C
United States, India, China

Portfolio highlights

Wonder — Introducing a new kind of home dining experience. Currently available in areas of New Jersey.
Foundry — Elastic cloud infrastructure built for machine learning.
Avenzo Therapeutics — Developing the next generation of oncology therapies for patients.

Aravis is the first independent Swiss on-shore private equity house, an established investor in the renewable energy and life science spaces. We are a "hands-on" investor taking leading positions and understanding the balance between finance, commercial assets and people. With this distinct and crafted approach, we are serving over 30leading investors including corporates, pension funds, government funds, insurance companies and family offices. Currently actively managing more than a quarter of a billion Swiss francs, we have a cumulative history of investments in over 100 companies. These have resulted in several noticeable exits including the divestment of several renewable energy companies and a number of life science reverse take-overs, listings and trade sales. Our many years of experience in the Swiss fund industry have enabled us to establish a platform with a comprehensive offering of investment, accounting, regulatory and reporting expertise. Located in Zurich, Aravis was founded in 2001.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
Switzerland, United States, Denmark

Portfolio highlights

Bird Rock Bio — We are a biopharmaceutical company focused on the development of proprietary cannabinoid derivatives for the treatment of glaucoma and other diseases with significant unmet medical needs. Our innovative approach to drug development combines strong science with the drive to find solutions where the need is the greatest.
Synaffix BV — Synaffix BV is a clinical-stage, Netherlands-based biotech company that has established a proprietary antibody-drug conjugate (ADC) technology platform that enhances efficacy and tolerability compared to all 3 major clinical-stage ADC technologies. We have a 'one-stop' technology offering (including 4 different ADC payloads) thatenables the development of proprietary ADCs from any antibody and our patent portfolio provides patent protection of resulting Products through at least 2035.Our business model is technology out-licensing and we regularly engage in research collaborations with other companies that are interested in developing highly competitive ADC products for their own pipelines.Disclosed partnerships to date include those with ADC Therapeutics and Mersana Therapeutics
Bellerophon Therapeutics — Bellerophon Therapeutics LLC is a clinical stage biotherapeutics company focused on developing innovative therapies at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary and cardiac diseases. Two of the company's product candidates are based on its proprietary pulsatile nitricoxide delivery device, INOpulse®, and are in Phase 2 clinical trials – one for the treatment of PAH and a second for the treatment of PH-COPD. The company's third product candidate, bioabsorbable cardiac matrix (BCM), is an injectable device currently undergoing a feasibility clinical trial, which is a CE mark registration trial in the European Union and is comparable to a Phase 2 trial in U.S. drug development, for the prevention of cardiac remodeling and subsequent congestive heart failure following acute myocardial infarction (heart attack).

Donations enable exceptional things to happen and contribute to solutions for the great challenges of our time.

Investment focus

Information Technology, Medical Device, Health Care
Seed, Grant, Series A
Switzerland

Portfolio highlights

DuraMon — DuraMon provides sensor for monitoring durability in concrete.
Rrreefs — Our mission is to regenerate degraded coral reefs at global scale - restoring rich marine biodiversity for a healthy ocean.
Positrigo — NeuroLF is an ultra-compact brain Positron Emission Tomography system. Our technology makes functional imaging accessible for people worldwide.

EIT Health is a network of best-in-class health innovators backed by the EU. We deliver solutions to enable European citizens to live longer, healthier lives.

Investment focus

Health Care, Medical Device, Medical
Grant, Pre-Seed, Seed
United Kingdom, Spain, Ireland

Portfolio highlights

Ochre Bio — Ochre Bio is developing therapies for the biggest liver health challenges.
Trak — Do you know TRAK's tele rehabilitation software? Get more clinical performance and grow your physical therapy business, request a trial!
Nanordica Medical — Nanordica Medical develops novel nanoparticle-based antibacterial wound care products.

Aargauische Kantonalbank (AKB) is a classical universal bank for private and corporate clients and institutional investors. They offer comprehensive services in all areas of banking. Their strengths include the needs-based, personalized and comprehensive advice and a comprehensive and competent care. The AKB has 31 offices in the canton of Aargauand the adjacent area Solothurn Olten-Gösgen-Gäu. Their company has about 790 employees and about 79 students. They serve approximately 230,000 customers. The AKB has been awarded by the rating agency Standard & Poor's AA + rating.

Investment focus

Medical Device, Dental, Biotechnology
Series B, Series A, Seed
Switzerland

Portfolio highlights

Peripal — Introduction to Peripal and what we do. Peripal AG manufactures and distributes the patient assist device PeriSafe to allow more patients to perform peritoneal dialysis at home.
InterAx Biotech Ltd — InterAx Biotech integrates experimental and computational pharmacology to reveal critical properties of novel GPCR drug candidates. Work with us now!
ELDICO Scientific — ELDICO Scientific AG (The Electron Diffraction Company) is a Swiss hardware company founded in 2019 and based in the Switzerland Innovation Park Innovaare at the Paul Scherrer Institute (PSI), a globally leading Swiss research institute for natural and engineering sciences. ELDICO develops, manufactures and sells novel instruments for electrondiffraction in crystallography, enabling nanocrystalline solid state analysis in the sub-micrometer range. Specific instruments are not yet available on the market today. ELDICO will be launching the first instrument specifically designed for nano-crystallographic investigations. The proof of concept was achieved in 2018 (ETH Zurich, C-CINA Basel) as part of a Nano-Argovia project of the Swiss Nanoscience Institute (SNI) on scientifically and industrially relevant samples. It was published in 2018 and awarded as a Top 5 "Breakthrough of the Year 2018" by leading scientific journal SCIENCE. In 2020, ELDICO took second place in the competition for the prestigious pioneer prize awarded by Technopark Zurich and the Zürcher Kantonalbank (ZKB).

Aglaia is founded on the principle that the willingness to take risks on the very early stage ventures of today results in opportunities that may grow into the winning companies of tomorrow. As such, we are typically the first provider of capital for startup and early stage companies and a driving force behind product development. Since thenumber of technological discoveries in the biomedical field is growing fast, specialized knowledge regarding the translation of these discoveries into novel products is a prerequisite for success. Aglaia's focus on oncology is considered to be a differentiating asset. We invest in novel tools and technologies as well as components of contemporary drug development.Opportunities may be derived from research centers as well as from corporate spinouts. We select, develop and commercialize promising technologies up to a level where the technology becomes attractive to larger investors or pharmaceutical and biotech companies.

Investment focus

Biotechnology, Therapeutics, Pharmaceutical
Series A, Series B, Seed
The Netherlands, United States, Switzerland

Portfolio highlights

Inthera Bioscience — Inthera Bioscience is a Switzerland-based private biopharmaceutical company developing targeted small molecule therapies for solid tumors. It is focused on developing inhibitors of intracellular protein-protein interactions employing a proprietary technology platform. The company is headquartered in Zürich, Switzerland.
InteRNA Technologies — A Dutch clinical-stage biotech company InteRNA Technologies is a Dutch clinical-stage biotech company developing a pipeline of proprietary RNA therapeutics targeting key processes in initiation and progression of human diseases, with a focus on cancer. Selected through its leading microRNA (miRNA) discovery and functional validation technology platform and enabled with a 3rd-generation drug delivery
Sapreme Technologies — Enabling endosomal escape

Investors by industry

Media (entertainment)

EdTech

Consumer

Climate